Clinical trial
Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
NCT05511844
Study timeline
Study start (actual)2022-10-03Date precision: day
Registry last updated2025-07-04
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
HER2-positive Breast Cancerunresolved
HER-2 Protein Overexpressionunresolved
HER-2 Gene Amplificationunresolved
HER2 Gene Mutationunresolved
Interventions
ORM-5029DRUG
Sponsors & collaborators
Orum Therapeutics USA, Inc.lead sponsor
Mapped research locations
New YorkNew York, United States2HoustonTexas, United States1BostonMassachusetts, United States1Los AngelesCalifornia, United States1St LouisMissouri, United States1San AntonioTexas, United States1NashvilleTennessee, United States1SeattleWashington, United States1BirminghamAlabama, United States1FairfaxVirginia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05511844 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.